Complement and anti-α-galactosyl natural antibody-mediated inactivation of murine retrovirus occurs in adult serum but not in umbilical cord serum

Gene Therapy

Volumn 6, Issue 1, 1999, Pages 146-148

  Agrawal, R S ^a,b   Karhu, K ^a   Laukkanen, J ^a   Kirkinen, P ^a   Yla Herttuala S ^a   Agrawal, Y P ^a,b  

^a KUOPIO UNIVERSITY HOSPITAL   (Finland)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Complement; Cord blood serum; Galactosyl antibody; Gene therapy; Retrovirus

Indexed keywords

AUTOANTIBODY; COMPLEMENT; COMPLEMENT COMPONENT C1Q; VIRUS VECTOR;

ARTICLE; GENE THERAPY; GENE TRANSFER; GENETIC TRANSDUCTION; HUMAN; PRIORITY JOURNAL; RETROVIRUS; TIME; UMBILICAL CORD BLOOD; VIRUS INACTIVATION;

ADULT; ANTIBODIES, VIRAL; COMPLEMENT SYSTEM PROTEINS; FETAL BLOOD; GENE THERAPY; GENETIC VECTORS; HUMANS; INFANT, NEWBORN; LEUKEMIA VIRUS, MURINE; TRANSFECTION; TRISACCHARIDES;

MURINAE; UNIDENTIFIED RETROVIRUS;

EID: 0032921773     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300794     Document Type: Article

References (21)

1. Miller AD. Human gene therapy comes of age. Nature 1992; 375: 455-460.
2. Oldfield EH et al. Gene therapy for the treatment of brain tumors using intra-tumoral transduction with the thymidine kinase gene and intravenous gancyclovir. Hum Gene Ther 1993; 4: 39-69.
3. Rollins SA et al. Retroviral vector producer cell killing in human serum is mediated by natural antibody and complement: strategies for evading the humoral immune response. Hum Gene Ther 1996; 7: 619-626.
4. Takeuchi Y et al. Type C retrovirus inactivation by human complement is determined by both the viral genome and producer cell. J Virol 1994; 68: 8001-8007.
5. Cosset F-L et al. High-titer packaging cells producing recombinant retroviruses resistant to human serum. J Virol 1995; 69: 7430-7436.
6. Rother RP et al. A novel mechanism of retrovirus inactivation in human serum mediated by anti-α-galactosyl natural antibody. J Exp Med 1995; 182: 1345-1355.
7. Andreadis S, Palsson BO. Coupled effects of polybrene and calf serum on the efficiency of retroviral transduction and the stability of retroviral vectors. Hum Gene Ther 1997; 8: 285-291.
8. + cells. Exp Hematol 1996; 24: 738-747.
9. - hematopoietic progenitor cells. Gene Therapy 1997; 4: 918-927.
10. Hayashi S et al. Establishment of complement-resistant retroviral vector by homologous restriction factor 20 gene. Gene Therapy 1997; 5: 282-285.
11. Rigg RJ et al. A novel human amphotropic packaging cell line: high titer, complement resistance and improved safety. Virology 1996; 218: 290-295.
12. Pensiero MN, Wysocki CA, Nader K, Kikuchi GE. Development of amphotropic murine retrovirus vectors resistant to inactivation by human serum. Hum Gene Ther 1996; 7: 1095-1101.
13. Takeuchi Y et al. Sensitization of rhabdo-, lenti-, and spuma-viruses to human serum by galactosyl(α1-3)galactosylation. J Virol 1997; 71: 6174-6178.
14. Rother RP, Squinto SP, Mason JM, Rollins SA. Protection of retroviral particles in human blood through complement inhibition. Hum Gene Ther 1995; 6: 429-435.
15. Sekhar M, Yu JM, Soma T, Dunbar CE. Murine long-term repopulating ability is compromised by ex vivo culture in serum-free medium despite preservation of committed progenitors. J Hematother 1997; 6: 543-549.
16. Cooper NR, Jensen FC, Raymond MW, Oldstone MBA. Lysis of RNA tumor viruses by human serum: direct antibody-independent triggering of the classical complement pathway. J Exp Med 1976; 144: 970-984.
17. Bartholomew RM, Esser AF. Mechanism of antibody-independent activation of the first component of complement (C1) on retrovirus membranes. Biochemistry 1980; 19: 2847-2853.
18. Bartholomew RM, Esser AF, Muller-Eberhard HJ. Lysis of oncornaviruses by human serum: isolation of the viral complement (C1) receptor and identification as p15E. J Exp Med 1978; 147: 844-853.
19. Russell DW, Berger MS, Miller AD. The effects of human serum and cerebrospinal fluid on retroviral vectors and packaging cell lines. Hum Gene Ther 1995; 6: 635-649.
20. Shimizu K et al. Infectious retrovirus is inactivated by serum but not by cerebrospinal fluid or fluid from tumor bed in patients with malignant glioma. Jpn J Cancer Res 1995; 86: 1010-1013.
21. Kohn DB, Parkman R. Gene therapy for newborns. FASEB J 1997; 11: 635-639.